Paxlovid looked like a COVID game-changer, but in vaccinated adults the real story is far more complicated

The results of two clinical trials—led by the Upstream Lab at St. Michael’s Hospital in Toronto and Oxford University, published in the New England Journal of Medicine—provide new evidence to consider when funding, prescribing, or taking Paxlovid to treat COVID-19.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup